ADRB2 and chronic kidney disease: With regard to downstream signals such as MAPK, agonists of the beta 2 adrenergic receptor, which can regulate this pathway, have recently been shown to be protective in CKD patients, with supporting data showing a reversal of phenotype in a DKD mouse model58.